TXG250117P25000
- 0.00
- 0.000.00%
10x Genomics Newsroom
10x Genomics: Strong Revenue Recovery and Promising Growth Opportunities Support Buy Rating
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $18 to $28
Morgan Stanley Maintains Overweight on 10x Genomics, Lowers Price Target to $28
10x Genomics Analyst Ratings
10X Genomics Shares Rise on Q4 Sales Beat
10x Genomics | 8-K: 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $19 to $23
TD Cowen Keeps Their Hold Rating on 10x Genomics (TXG)
Balanced Outlook on 10x Genomics: Strong Q4 Performance Amidst Cautionary Signals
Express News | Reported Sunday, 10x Genomics Reports $610.8M In 2024 Revenue (-1% YoY), $165M Q4 Revenue (-10% YoY), And $393M In Cash Reserves
Analysts' Top Healthcare Picks: Exagen (XGN), 10x Genomics (TXG)
Express News | 10X Genomics Q4 Revenue USD 165 Million Vs. IBES Estimate USD 153.4 Million
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
Colorado's Most Expensive Home for Sale Is Listing for $78 Million -- WSJ
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cathie Wood's ARK ETF Adjusts, Adds 10X Genomics, Sells Rocket Lab
Bruker to Seek Injunction, Appeal After Court Sides With 10x Genomics in Patent Dispute
Bruker Plans to File for a Stay of NanoString GeoMX Injunction Ruling
Cathie Wood's ARK Investment Buys 36K Shares of 10x Genomics Today
10x Genomics Secures Court Injunction Against Bruker's Sale of GeoMx Products in US